AIM: Low-grade inflammation plays a pivotal role in atherogenesis in type 2 diabetes. Next to its antithrombotic effects, several lines of evidence demonstrate anti-inflammatory properties of aspirin. We determined the effects of aspirin on inflammation - represented by C-reactive protein (CRP) and interleukin-6 (IL-6) - in type 2 diabetic subjects without cardiovascular disease and assessed differential effects of aspirin 300 mg compared with 100 mg. METHODS: A randomized, placebo-controlled, double-blind, crossover trial was performed in 40 type 2 diabetic patients. In two periods of 6 weeks, patients used 100 or 300 mg aspirin and placebo. Plasma CRP and IL-6 levels were measured before and after both periods. RESULTS: Use of aspirin resulted in a CRP reduction of 1.23 +/- 1.02 mg/l (mean +/- s.e.m.), whereas use of placebo resulted in a mean increase of 0.04 +/- 1.32 mg/l (P = 0.366). Aspirin reduced IL-6 with 0.7 +/- 0.5 pg/ml, whereas use of placebo resulted in a mean increase of 0.2 +/- 0.8 pg/ml (P = 0.302). There were no significant differences in effects on CRP and IL-6 between 100 and 300 mg aspirin. CONCLUSIONS: Our results indicate that a 6-week course of aspirin does not improve low-grade inflammation in patients with type 2 diabetes without cardiovascular disease, although a modest effect could not be excluded. No significant differential effects between aspirin 100 and 300 mg were found.
RCT Entities:
AIM: Low-grade inflammation plays a pivotal role in atherogenesis in type 2 diabetes. Next to its antithrombotic effects, several lines of evidence demonstrate anti-inflammatory properties of aspirin. We determined the effects of aspirin on inflammation - represented by C-reactive protein (CRP) and interleukin-6 (IL-6) - in type 2 diabetic subjects without cardiovascular disease and assessed differential effects of aspirin 300 mg compared with 100 mg. METHODS: A randomized, placebo-controlled, double-blind, crossover trial was performed in 40 type 2 diabeticpatients. In two periods of 6 weeks, patients used 100 or 300 mg aspirin and placebo. Plasma CRP and IL-6 levels were measured before and after both periods. RESULTS: Use of aspirin resulted in a CRP reduction of 1.23 +/- 1.02 mg/l (mean +/- s.e.m.), whereas use of placebo resulted in a mean increase of 0.04 +/- 1.32 mg/l (P = 0.366). Aspirin reduced IL-6 with 0.7 +/- 0.5 pg/ml, whereas use of placebo resulted in a mean increase of 0.2 +/- 0.8 pg/ml (P = 0.302). There were no significant differences in effects on CRP and IL-6 between 100 and 300 mg aspirin. CONCLUSIONS: Our results indicate that a 6-week course of aspirin does not improve low-grade inflammation in patients with type 2 diabetes without cardiovascular disease, although a modest effect could not be excluded. No significant differential effects between aspirin 100 and 300 mg were found.
Authors: Sara E Espinoza; Robyn L Woods; A R M Saifuddin Ekram; Michael E Ernst; Galina Polekhina; Rory Wolfe; Raj C Shah; Stephanie A Ward; Elsdon Storey; Mark R Nelson; Christopher M Reid; Jessica E Lockery; Suzanne G Orchard; Ruth Trevaks; Sharyn M Fitzgerald; Nigel P Stocks; Andy Chan; John J McNeil; Anne M Murray; Anne B Newman; Joanne Ryan Journal: J Gerontol A Biol Sci Med Sci Date: 2022-10-06 Impact factor: 6.591
Authors: Elizabeth D Kantor; Johanna W Lampe; Thomas L Vaughan; Ulrike Peters; Colin D Rehm; Emily White Journal: Am J Epidemiol Date: 2012-11-08 Impact factor: 4.897
Authors: Angharad G Davis; Sean Wasserman; Mpumi Maxebengula; Cari Stek; Marise Bremer; Remy Daroowala; Saalikha Aziz; Rene Goliath; Stephani Stegmann; Sonya Koekemoer; Amanda Jackson; Louise Lai Sai; Yakub Kadernani; Thandi Sihoyiya; C Jason Liang; Lori Dodd; Paolo Denti; Thomas Crede; Jonathan Naude; Patryk Szymanski; Yakoob Vallie; Ismail Banderker; Shiraz Moosa; Peter Raubenheimer; Rachel P J Lai; John Joska; Sam Nightingale; Anna Dreyer; Gerda Wahl; Curtis Offiah; Isak Vorster; Sally Candy; Frances Robertson; Ernesta Meintjes; Gary Maartens; John Black; Graeme Meintjes; Robert J Wilkinson Journal: Wellcome Open Res Date: 2021-06-01